Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan G Holtan, MD, Claudio G. Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-136479

Published: 2020

Journal Articles

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Blood (2020) 136 (Supplement 1): 44–46.

https://doi.org/10.1182/blood-2020-136337

Published: 2020

Journal Articles

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Rose Wangen, Dixie Lewis, RN,BA, JoAnn Knox, Martin Schroeder, Martin Felices, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136398

Published: 2020

Journal Articles

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E. Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan Holtan, MD, Claudio G Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2019) 134 (Supplement_1): 2009.

https://doi.org/10.1182/blood-2019-123421

Published: 2019

Journal Articles

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Bhaskar Kolla, MBBS, Nurul Aidah Abdul Halim, MBBS, Zohar Sachs, MD PhD, Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Fiona He, MD, Lao Zhentang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 3432.

https://doi.org/10.1182/blood-2019-123306

Published: 2019

Journal Articles

History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes

Michelle A. Roesler, BS, Amy Linabery, PhD MS, Michaela Richardson, MPH, Adina Cioc, MD, Betsy A Hirsch, PhD, Phuong L. Nguyen, MD, Erica D. Warlick, MD, Jenny Poynter, PhD

Blood (2019) 134 (Supplement_1): 3014.

https://doi.org/10.1182/blood-2019-130940

Published: 2019

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Journal Articles

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

Nelli Bejanyan, MD, Mei-Jie Zhang, PhD, Khalid Bo-Subait, Hai-Lin Wang, MPH, Erica D. Warlick, MD, Claudio G Brunstein, MD PhD, Brenda M Sandmaier, MD, Mark Litzow, MD, Partow Kebriaei, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD

Blood (2019) 134 (Supplement_1): 4603.

https://doi.org/10.1182/blood-2019-123513

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

Predicted Leukocyte Telomere Length and Risk of Myeloid Neoplasms

Jenny Poynter, PhD, Spencer Kelley, Marina Marcato, Erica Langer, Anthony J Hooten, Mary Rachel Stimson, Michelle A. Roesler, BS, Phuong L. Nguyen, MD, Adina Cioc, MD, Erica D. Warlick, MD, Nathan Pankratz

Blood (2019) 134 (Supplement_1): 1335.

https://doi.org/10.1182/blood-2019-131224

Published: 2019

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Veronika Bachanova, MD PhD, David H. McKenna, MD, Xianghua Luo, PhD, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD MS, Erica D. Warlick, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Guy Brachya, PhD, Tony Peled, MSc, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 777.

https://doi.org/10.1182/blood-2019-130476

Published: 2019

Journal Articles

First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation

Margaret L. MacMillan, MD, Keli Lee Hippen, PhD, David H. McKenna, MD, Todd E. DeFor, MS, Erica D. Warlick, MD, Claudio G Brunstein, MD PhD, Jeffrey S. Miller, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, John E. Wagner, MD

Blood (2018) 132 (Supplement 1): 2112.

https://doi.org/10.1182/blood-2018-99-113100

Published: 2018

Journal Articles

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Blood (2018) 132 (Supplement 1): 71.

https://doi.org/10.1182/blood-2018-99-113564

Published: 2018

Journal Articles

Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Michael K Keng, MD, Samer K. Khaled, MD, Brenda Cooper, MD, Erica D. Warlick, MD, David Ramies, MD, Silvia Mappa, MD, Ehab L. Atallah, MD

Blood (2018) 132 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2018-99-112741

Published: 2018

Journal Articles

Factors Predicting Early Mortality in Newly Diagnosed Myelodysplastic Syndrome (MDS): A Population Based Study

Annie M. Jacobsen, MD, Jenny Poynter, PhD, Michaela Richardson, MPH, Phuong L. Nguyen, MD, Betsy A Hirsch, PhD, Adina Cioc, MD, Michelle A. Roesler, BS, Erica D. Warlick, MD

Blood (2018) 132 (Supplement 1): 4369.

https://doi.org/10.1182/blood-2018-99-112319

Published: 2018

Journal Articles

Reduced Intensity Conditioning for Allogeneic Transplantation: Modified Fludarabine Dose Plus Cyclophosphamide/Total Body Irradiation Yields Promising Outcomes

Erica D. Warlick, MD, Todd E. DeFor, MS, Celalettin Ustun, MD, Nelli Bejanyan, MD, Claudio G Brunstein, MD PhD, Margaret L. MacMillan, MD, Daniel J. Weisdorf, MD

Blood (2017) 130 (Supplement 1): 5465.

https://doi.org/10.1182/blood.V130.Suppl_1.5465.5465

Published: 2017

Journal Articles

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

Tara L. Lin, MD, Geoffrey L. Uy, MD, Matthew J. Wieduwilt, Laura F. Newell, MD, Robert K. Stuart, MD, Bruno C Medeiros, MD, Gary J. Schiller, Eric Rubenstein, MD, Wendy Stock, MD, Erica D. Warlick, MD, Matthew Foster, Dale L. Bixby, Nikolai A. Podoltsev, MD PhD, Qi An, Stefan Faderl, Arthur C. Louie, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 1698.

https://doi.org/10.1182/blood.V130.Suppl_1.1698.1698

Published: 2017

Journal Articles

CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics

Martin Felices, PhD, Dhifaf Sarhan, PhD, Ludwig Brandt, Karolin Guldevall, Ron McElmurry, Alexander Lenvik, Sami Chu, Jakub Tolar, MD PhD, Elizabeth Taras, Stephen R Spellman, MS, Erica D. Warlick, MD, Michael R. Verneris, MD, Sarah Cooley, MD, Daniel Weisdorf, MD, Bruce R. Blazar, MD, Bjorn Onfelt, PhD, Dan Vallera, PhD, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 4291.

https://doi.org/10.1182/blood.V128.22.4291.4291

Published: 2016

Journal Articles

Validation of a Modified Comorbidity Index for Allogeneic Hematopoietic Cell Transplant

Todd E. DeFor, MS, Chap Le, PhD, Angela R Smith, MD MS, Erica D. Warlick, MD, Nelli Bejanyan, MD, Daniel J. Weisdorf, MD

Blood (2016) 128 (22): 1167.

https://doi.org/10.1182/blood.V128.22.1167.1167

Published: 2016

Journal Articles

High Peripheral Blood Stem Cell (PBSC) CD34+ Cell Dose Increases the Risk of Chronic Gvhd after Human Leukocyte Antigen (HLA) Matched Sibling Transplantation

Ezzideen Barjes Alrawi, MD, Erica D. Warlick, MD, Qing Cao, MS, Mukta Arora, MD, Shernan G. Holtan, MD, Tim Krepski, Michael R. Verneris, MD, John Wagner, Daniel J. Weisdorf, MD, Claudio G Brunstein, MD

Blood (2016) 128 (22): 5877.

https://doi.org/10.1182/blood.V128.22.5877.5877

Published: 2016

NARROW

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Predicted Leukocyte Telomere Length and Risk of Myeloid Neoplasms

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Factors Predicting Early Mortality in Newly Diagnosed Myelodysplastic Syndrome (MDS): A Population Based Study

Reduced Intensity Conditioning for Allogeneic Transplantation: Modified Fludarabine Dose Plus Cyclophosphamide/Total Body Irradiation Yields Promising Outcomes

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics

Validation of a Modified Comorbidity Index for Allogeneic Hematopoietic Cell Transplant

High Peripheral Blood Stem Cell (PBSC) CD34+ Cell Dose Increases the Risk of Chronic Gvhd after Human Leukocyte Antigen (HLA) Matched Sibling Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only